This podcast is brought to you by Outcomes Rocket, yoru exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com
At-home blood testing is moving diagnostics out of clinics and into people’s lives, removing friction while expanding access to critical health insights.
In this episode, Michael Dubrovsky, co-founder and CEO of SiPhox Health, discusses how his team is reimagining blood testing through painless at-home collection and advanced diagnostics focused on longevity and overlooked biomarkers.He explains why customary blood testing in the U.S. is burdened by complexity, how SiPhox fills gaps left by primary care, and the growing consumer demand for deeper health data. Michael shares the origins of the company’s silicon photonics technology, the challenges of clinician trust and FDA clearance, and how home testing is already saving lives by identifying conditions like heart disease and hemochromatosis earlier. He also explores B2B use cases,funnel optimization,health equity,and why betting on fully home-based testing is a bold but necesary move for the future of healthcare.
Tune in and learn how at-home diagnostics could fundamentally change how care is delivered and experienced!
Why SiPhox Exists: Addressing Gaps in Healthcare
Michael Dubrovsky founded SiPhox Health to tackle the inefficiencies and limitations of the current U.S. healthcare system,specifically regarding blood testing.He observed that traditional primary care often struggles to provide complete preventative health insights due to time constraints and a focus on reactive treatment. Consumers, meanwhile, are increasingly proactive about their health and desire more detailed data. SiPhox aims to bridge this gap by offering accessible, at-home blood tests that focus on longevity and biomarkers often overlooked by standard panels. The company’s core innovation lies in it’s use of silicon photonics, a technology originally developed for telecommunications, adapted to analyze blood with unprecedented accuracy and ease.
How SiPhox Works: Technology, Regulation, and Impact
SiPhox’s at-home testing process involves a simple finger-prick blood collection method, followed by analysis using their silicon photonics platform. The technology allows for a wide range of biomarkers to be measured from a small sample. However, bringing this technology to market wasn’t without hurdles. Dubrovsky detailed the challenges of gaining clinician trust – convincing healthcare professionals to accept and integrate at-home testing into their practices – and navigating the rigorous FDA clearance process. Despite these obstacles, SiPhox has already demonstrated the life-saving potential of its technology, with early detection of conditions like heart disease and hemochromatosis (an iron overload disorder) through at-home testing. The company is also exploring B2B applications, working with employers and wellness programs to offer preventative health screenings. Dubrovsky emphasized the importance of health equity, aiming to make advanced diagnostics accessible to a wider population.
What’s Next: the Future of At-Home Diagnostics
SiPhox’s long-term vision is a future where healthcare is proactive,personalized,and largely home-based. Dubrovsky believes that fully home-based testing, while a bold move, is essential for addressing the limitations of the current system and empowering individuals to take control of their health. The company is focused on optimizing its testing funnel, expanding its biomarker panel, and continuing to demonstrate the clinical validity of its technology. Ultimately, SiPhox aims to fundamentally change how care is delivered and experienced, shifting from reactive treatment to preventative wellness.
Resources:
